A

Apellis Pharmaceuticals

D
APLS
USD
0.69
(2.4573%)
Market Closed
52,204.00
Volume
-1.29
EPS
-
Div Yield
-10.577206
P/E
3,503,217,256.56
Market Cap
Today
-0.3809%
1 Week
5.539%
1 Month
4.809%
6 Months
-34.569%
12 Months
-39.175%
Year To Date
-51.930%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ABUS
-0.195
(-4.9618%)
USD
AMGN
AMGN
0.28
(0.087%)
USD
A
ANAB
-0.695
(-3.1292%)
USD
A
ARWR
0.055
(0.2579%)
USD
A
ATNX
-0.34
(-19.6532%)
USD
B
BIIB
-0.32
(-0.1837%)
USD
B
BGNE
3.67
(1.8053%)
USD
BMY
BMY
-1.66
(-2.9454%)
USD
C
CRBP
-0.36
(-1.9027%)
USD
D
DRNA
(%)
USD
E
EXEL
0.28
(0.7883%)
USD
GE
GE
-1.78
(-0.9854%)
USD
GSK
GSK
0.89
(2.4881%)
USD
I
INCY
2.2
(2.7445%)
USD

Title:
Apellis Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Do you need help or have a question?
Contact Us